This research investigates a new targeted treatment strategy for kidney cancer by inhibiting the cancer-promoting protein PIM1 while enhancing TRAIL-mediated apoptosis. Together with the FDA-approved drug ONC201, this combination restores cancer cells' ability to self-destruct, offering a promising therapeutic approach now being evaluated in preclinical studies.

This research investigates how calpain, a protein that regulates cell movement, contributes to breast cancer metastasis. By disrupting calpain in tumor cells, researchers show reduced spread to the lungs in mouse models. Targeting calpain may improve combination therapies and offer new treatment strategies for metastatic breast cancer patients.